The Supreme Court today issued notice on a public interest litigation seeking quashing of approvals or licenses granted for manufacturing of 'Liposomal Amphotericin B' for emergency use during the Covid-19 pandemic.

The PIL, filed by one Rajendra Prasad, also seeks stoppage of distribution and destruction of existing stock of the said medication, in accordance with appropriate safety protocols.

A bench of Justices Vikram Nath and Sandeep Mehta passed the order, calling for the response of the Union of India, the Drug Controller General of India and pharmaceutical companies including Bharat Serum and Vaccines Ltd., Cipla, Sun Pharma, Emcure, NATCO Pharma, etc.

As per the petitioner, the medication continues to be manufactured by the respondent-companies on expired emergency authorizati

See Full Page